bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
71%Questions answered2Evaded / deflected12Questions auditedContradictedNumbers vs filing
Partial answer
High priority
Outlook on Indian market and evolution of India focus.
Asked by Mikaela Franceschina, Barclays
Management gave qualitative direction but no specific growth numbers or timeline.
no specific timelineno quantitative growth target
Read the exchange
Question
Given India remains a priority market for you, can you just provide an outlook on your Indian market, and just elaborate a bit more on the evolution in your India focus?
Erez Israeli, CEO
The main focus is licensing and collaborating with partners to bring innovation to India. The focus portfolio is growing double digits, and that's what you're going to see from quarter to quarter.
Answered
High priority
Nature of observations for biologics plant and CAPA needed.
Asked by Kunal Dhamesha, Macquarie
Management provided specific timeline and nature of actions.
Read the exchange
Question
On the main observation for the biologics plant that we have received, can you please elaborate what is the nature of these observations, and whether we need to undertake some corrective and preventive actions there?
Erez Israeli, CEO
I believe that those observations are addressable. We are going to address all of them in the beginning of November. Some will require CAPA, which will take us to January.
Partial answer
Medium priority
Reason for PSAI gross margin decline and benefit from lower API prices.
Asked by Kunal Dhamesha, Macquarie
Management did not directly address the margin decline reason or benefit from lower API prices.
no specific margin explanationreframed to growth
Read the exchange
Question
If I look at the gross margin for that business has gone down. Is it primarily due to the unfavorable pricing environment? And if that is the case, do we get the benefit of lower API prices in our global generic business?
Erez Israeli, CEO
I don't see such a decline in the API like it was in previous years. Most of the growth is coming from new products and launches. As we grow sales, we normally grow gross margins.
Evasive
High priority
Traction in Mayne acquisition portfolio and NuvaRing market share.
Asked by Neha Manpuria, Bank of America
Management gave no concrete evidence of traction and deferred to future discussions.
no specific volume datadeferred to future
Read the exchange
Question
Post nearly five to six months of integration into the Reddy's portfolio, have you seen traction in terms of our ability to gain more volume? Because we don't see that in a product like NuvaRing, which is stuck at that 2%-3% market share.
Erez Israeli, CEO
Each product has different timing for customer RFP. I believe this will grow and pick up volumes as these timelines will be there. Most discussions will likely happen in the second half of the year.
Answered
High priority
Timeline for double-digit growth in India business.
Asked by Neha Manpuria, Bank of America
Management gave a clear timeline (this fiscal year) and explained the lag.
Read the exchange
Question
We have guided to wanting to grow higher than the market, double digit in this business, but for several quarters now, that hasn't been the case. When do we think we get to that growth trajectory?
Erez Israeli, CEO
Likely that we are going to see it already this year, this fiscal. The innovation launches are from deals signed a year ago. It takes about 12-18 months from signing to product approval.
Answered
High priority
Timeline for biosimilar rituximab in U.S. and Europe.
Asked by Saion Mukherjee, Nomura
Management provided specific timeline and status.
Read the exchange
Question
Can you tell us on biosimilar rituximab, what's the timeline you're looking at now for the U.S. and European markets?
Erez Israeli, CEO
We submitted it in April. We just got the pre-approval inspection, so we will answer it by November. If everything is okay, we will be able to launch it in the beginning of FY 2025.
Evasive
High priority
Quarter-on-quarter revenue dynamics in U.S. by product bucket.
Asked by Saion Mukherjee, Nomura
Management did not provide the requested breakdown between Revlimid and base business.
incomplete answerno breakdown given
Read the exchange
Question
If I look at quarter-on-quarter revenue in the U.S., which is sort of flattish, can you just share the dynamics with respect to main contribution Revlimid and the base business, how each of these buckets have moved quarter-on-quarter?
Erez Israeli, CEO
Most of the growth came from volume growth and the main.
Answered
Medium priority
Sustainability of government grants and PLI visibility.
Asked by Surya Patra, PhillipCapital
Management confirmed sustainability and gave directional guidance.
Read the exchange
Question
In the previous year, we have seen something around INR 300 crore. In the first half, it is more than INR 200 crore. What is the visibility here, and how long can this sustain? And is this relating to the PLI only or something else?
Parag Agarwal, CFO
This includes PLI and other export incentives. Overall, our PLI and other export incentives this year will be markedly higher than last year. For the next several quarters, we expect it to be meaningful.
Partial answer
High priority
Readiness for GLP-1 opportunity and potential market size.
Asked by Aman Vij, Astute Investment Management
Management confirmed readiness but gave no specifics on size or portfolio.
no specific market size estimateno details on readiness
Read the exchange
Question
How well are we placed as a company to take the advantage of the upcoming GLP-1 opportunity? In terms of launch ready, are we ready? And do you think this product category can be like a $300 million-$500 million kind of category for the next five years?
Erez Israeli, CEO
We are going to be there, definitely, day one. As for the size, I don't know, but obviously, I have a great belief in this category.
Answered
Medium priority
India business chronic therapy contribution and sales force size.
Asked by Damayanti Kerai, HSBC
Management provided specific percentages and headcount.
Read the exchange
Question
Can you tell us how much India sales is currently contributed by chronic therapies? And how many sales representatives you have for your India business, and do you have plan to expand on it?
Erez Israeli, CEO
The chronic is about 35% of the business. As for the numbers of sales people, it's a little bit more than 6,000 people, and will grow as we bring innovations.
Answered
Medium priority
India sales growth adjusted for discontinued products and NLEM.
Asked by Gagan Thareja, ASK Investment Managers
Management gave a specific growth rate.
Read the exchange
Question
Adjusting for the discontinued products, what would have the India sales growth been year-on-year for the quarter?
Erez Israeli, CEO
Without these products and without NLEM, we are about mid-single digits for the quarter.
Answered
High priority
M&A strategy and comfortable leverage level.
Asked by Saion Mukherjee, Nomura
Management provided clear stance on deal size and leverage limit.
Read the exchange
Question
Are you looking at larger deals going ahead? Is there more activity that you're seeing on the M&A side? And what's the level of leverage that as a company you would be comfortable with?
Erez Israeli, CEO and Parag Agarwal, CFO
We are looking for all deals, small and bigger, but we are not in a rush. It has to be a good deal. (Parag) I would say 2x EBITDA is what we would be willing to go for.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| India sales growth adjusted for discontinued products and NLEM is mid-single digits. | 5% | 9% | Understated vs filing |
| PSAI gross margin is 18% for the quarter. | 18% | 31.7% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.